SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is actively discussed following strategic shifts, including a new "Meta Compute" initiative focused on scaling AI infrastructure through significant nuclear energy partnerships, alongside reported workforce reductions in its Reality Labs division. The community is sharply divided, with some investors questioning the large capital expenditure and perceived lack of immediate returns, while others view these investments as essential for long-term growth and AI leadership.

Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Travere Therapeutics Inc

Travere Therapeutics (TVTX) is highly volatile following its corporate update, which revealed the FDA requested additional clarification on clinical benefit for the FILSPARI label expansion in Focal Segmental Glomerulosclerosis (FSGS). This has triggered a significant sell-off as some investors anticipate a Complete Response Letter (CRL), while others view the drop as an overblown reaction, confidently buying the dip due to the company's strong existing IgA nephropathy (IgAN) drug sales and the potential for a first-ever FSGS therapy.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is a trending topic amidst its J.P. Morgan conference presentation, the appointment of a Chief Commercial Officer, and recent publication of promising Phase 2 data for its obesity asset, VK2735. The community is debating whether these developments signal an imminent partnership or acquisition, leveraging the drug's "best-in-class" potential and significant market demand. However, some express frustration over perceived delays in FDA guidance and leadership's communication style, leading to varied sentiment on its competitive positioning in the lucrative metabolic therapies space.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is a focal point of market discussion following reports of new tariffs on countries trading with Iran and an investigation into Fed Chair Powell, prompting concerns over market stability and central bank independence. Despite this significant news, the community remains sharply divided, with many advocating to "buy the dip" and anticipating further rallies, while others warn of perceived manipulation and a potential sharp market reversal. This divergence in sentiment underscores the current uncertainty as the tech-heavy ETF shows resilience.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingo is trending amid a recent CFO transition and its reaffirmed commitment to prioritizing user growth and product innovation, despite strong preliminary Q4 metrics. The stock's significant decline has sparked a heated debate, with bulls viewing it as an oversold opportunity supported by strong fundamentals and AI integration, while bears argue the business model is vulnerable to free AI alternatives and cite ongoing chart weakness.

Biodesix, Inc. provides blood-based diagnostics services for patients with lung disease. The firm offers GeneStrat, a genomic blood test for patients who have been diagnosed with advanced lung cancer and VeriStrat, a serum proteomic test that provides prognostic and predictive information for patients with non-small cell lung cancer. It also offers six diagnostic tests including: Nodify XL2, Nodify CDT, GeneStrat, VeriStrat, Bio-Rad SARS-CoV-2 ddPCR test and the Platelia SARS-CoV-2 test. The company was founded by David Brunel and Robert E. Cawthorn in 2005 and is headquartered in Louisville, CO.

Biodesix Inc

BDSX is trending due to strong preliminary Q4 and full-year 2025 results, which reported significant revenue growth and reaffirmed guidance for Adjusted EBITDA positivity. The community is actively discussing the stock's explosive volume and price action, with many speculating on continued momentum and a potential short squeeze. However, some investors express caution, pointing to the company's cash position and potential future dilution within the volatile biotech sector.

Teladoc Health, Inc. engages in the provision of telehealthcare services using a technology platform via mobile devices, the Internet, video and phone. It operates through the following segments: Teladoc Health Integrated Care, BetterHelp, and Others. The Teladoc Health Integrated Care segment offers virtual medical services. The BetterHelp segment includes virtual mental health and other wellness services. The company was founded in June 2002 by George Byron Brooks, Michael Gorton, and Gary Wald and is headquartered in New York, NY.

Teladoc Health Inc

Teladoc Health is trending amid intense community debate, fueled by its ongoing underperformance and deep frustration with current management's ability to deliver sustained profitability. However, many investors remain bullish, highlighting the company's position as a global leader in virtual care and its potential to capture a significant share of the rapidly expanding AI healthcare market. Recent partnerships, such as with TytoCare for at-home diagnostics, and anticipation around the $50 billion Rural Health Transformation Program are seen as key catalysts, driving speculation of a significant long-term rebound for the stock.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is a major talking point as the bank kicks off earnings season, with community discussions intensely focused on recent warnings about rising expenses and the potential impact of a proposed credit card interest rate cap. Investors are also digesting the bank's strategic move to take over the Apple Card program and its deeper foray into blockchain and tokenized funds, all while online chatter includes speculation regarding its market positions in commodities.

Gilat Satellite Networks Ltd. engages in the provision of broadband satellite communication and networking solutions and services. It operates through the following business segments: Fixed Networks, Mobility Solutions, and Terrestrial Infrastructure Projects. The Fixed Networks segment provides advanced fixed broadband satellite communication networks, satellite communication systems and associated professional services and comprehensive turnkey solutions and fully managed satellite network services solutions. The Mobility Solutions segment provides advanced on-the-move satellite communications equipment, systems, and solutions, including airborne, maritime and ground-mobile satellite systems and solutions. The Terrestrial Infrastructure Projects segment provides network infrastructure construction of the fiber and microwave network of PRONATEL in Peru. The company was founded by Yoel Gat, Gideon Kaplan, Amiram Levinberg, Joshua Levinberg, and Shlomo Tirosh in 1987 and is headquartered in Petah Tikva, Israel.

Gilat Satellite Networks

Gilat Satellite Networks is generating significant buzz following an oversubscribed private placement and a series of substantial contract wins across its multi-orbit SkyEdge IV platform and burgeoning defense solutions. The community is actively discussing the company's strong earnings momentum, raised guidance, and perceived undervaluation, viewing GILT as a compelling growth opportunity in the rapidly expanding satellite communications sector.

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Fortress Biotech Inc - 9.375% PRF PERPETUAL USD 25 - Ser A

Fortress Biotech's preferred shares (FBIOP) are trending following the recent approval of its subsidiary's drug, CUTX-101, which is anticipated to bring a valuable Priority Review Voucher. The community is buzzing about the potential for this monetization to drive significant upside for FBIOP, with many expecting it to lead to the reinstatement of cumulative dividends and address the perceived valuation gap with common stock.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 6.2% - Here's What Happened

Travere Therapeutics (NASDAQ:TVTX) Shares Down 6.2% - Time to Sell...

Travere Therapeutics Provides Corporate Update and 2026 Outlook

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that, based on preliminary and unaudited financial data, the Company expects total U.S. net product sales for the fourth quarter of 2025 to...

Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells $16,798.75 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 445 shares of the company's stock in a transaction on Tuesday, January 6th. The shares were sold at an average price...

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 6.1% - Time to Sell?

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 6.1% - Should You Sell...

Travere Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that Eric Dube, Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday...

Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4% Following Insider Selling

Travere Therapeutics (NASDAQ:TVTX) Trading Down 4% After Insider Selling...

Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 60,000 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider William Rote sold 60,000 shares of the firm's stock in a transaction dated Wednesday, December 24th. The shares were sold at an...

Travere Therapeutics (NASDAQ:TVTX) Insider Peter Heerma Sells 4,980 Shares

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Peter Heerma sold 4,980 shares of the company's stock in a transaction dated Wednesday, December 24th. The stock was sold at an...

Jula Inrig Sells 15,000 Shares of Travere Therapeutics (NASDAQ:TVTX) Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider Jula Inrig sold 15,000 shares of the company's stock in a transaction on Wednesday, December 24th. The shares were sold at an...

Travere Therapeutics (NASDAQ:TVTX) Insider Sells $2,406,000.00 in Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX - Get Free Report) insider William Rote sold 60,000 shares of the stock in a transaction dated Wednesday, December 24th. The stock was sold at an average price...

https://files.quartr.com/streams/2026-01-13/acf7962b-585c-4739-ba2f-038534a01096/2/live_transcript.jsonl?ref=U3RvY2t0d2l0cw==

44th Annual J.P. Morgan Healthcare Conference

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

Stocktwits

Stocktwits Polls

The market is reacting sharply to the FDA's request for additional clinical benefit clarification, causing significant price volatility.

Traders are aggressively "buying the dip" after the stock's unexpected 40% pre-decision drop, viewing current prices as a strong entry point.

Many users are anticipating a Complete Response Letter from the FDA following recent clarification requests, adding to market uncertainty.

The market highlights the unpredictable and "wild" nature of biotech stocks, particularly around critical FDA regulatory catalysts.

TVTX
Travere Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest TVTX News

TVTXTravere Therapeutics Inc